Praxis Precision Medicines Inc. (PRAX): Price and Financial Metrics
PRAX Price/Volume Stats
| Current price | $46.89 | 52-week high | $67.21 |
| Prev. close | $46.59 | 52-week low | $12.45 |
| Day low | $45.60 | Volume | 350,000 |
| Day high | $48.19 | Avg. volume | 216,358 |
| 50-day MA | $50.85 | Dividend yield | N/A |
| 200-day MA | $29.06 | Market Cap | 620.73M |
PRAX Stock Price Chart Interactive Chart >
Praxis Precision Medicines Inc. (PRAX) Company Bio
Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.
Latest PRAX News From Around the Web
Below are the latest news stories about PRAXIS PRECISION MEDICINES INC that investors may wish to consider to help them evaluate PRAX as an investment opportunity.
Wall Street Analysts Believe Praxis Precision Medicines, Inc. (PRAX) Could Rally 494.95%: Here's is How to TradeThe mean of analysts' price targets for Praxis Precision Medicines, Inc. (PRAX) points to a 495% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming MeetingsBOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida. Presentations at the American Epilepsy Society (AES) Annual Meeting, |
Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare ConferenceBOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am. The event will be available via live webcast throug |
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental EpilepsiesBOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that the European Medical Agency (EMA) has awarded its Priority Medicines (PRIME) designation for elsunersen (PRAX-222) for the treatment of SCN2A Gain of Function (GoF) developmental a |
PRAX Price Returns
| 1-mo | -10.53% |
| 3-mo | 25.31% |
| 6-mo | 179.11% |
| 1-year | 192.15% |
| 3-year | -89.42% |
| 5-year | N/A |
| YTD | 110.46% |
| 2023 | -37.59% |
| 2022 | -87.92% |
| 2021 | -64.19% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...